Prostate cancer
ACTfirst
A phase III, open-label, multi-center, randomized study comparing AAA817 plus ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer
Trial overview
Clinical Area
Theranostics
Disease
Prostate
Disease site
Genitourinary (GU)
Study Phase
III
Trial Identifiers
Registration number: NCT06855277
GenesisCare Location(s)
Principal Investigator(s)
··
··